Systemic and topical antiviral control of CMV anterior uveitis: TreatmentOutcomes
Official title: Systemic and Topical Antiviral Control of Cytomegalovirus Anterior uveitis: TreatmentOutcomes (STACCATO)
Funded at University of California, San Francisco · NIH-11517251 · Data updated 2026-11-12
A patient-focused look at how CMV eye inflammation in adults could be treated with pills, eye drops, or other strategies to prevent vision loss.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | June 1, 2026 |
| Project end | January 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $16,460 |
| NIH project number | 3UG1EY036344-01A1S1 |
| Project ID | NIH-11517251 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with CMV anterior uveitis or at risk of developing it, particularly those who may require antiviral therapy.
✕Less likely to help
Patients without CMV anterior uveitis or those not needing antiviral therapy may not benefit.
What this research studies
Cytomegalovirus anterior uveitis can cause serious eye inflammation and blindness, especially in adults. This grant explores different antiviral approaches, including oral valganciclovir and topical ganciclovir eye drops, to find the best way to control the disease while monitoring safety. Treatments will be studied in real patients through coordinated clinical activities at UC San Francisco to understand outcomes, side effects, and practical use in diverse populations. The goal is to identify clear guidelines so clinicians can choose effective and affordable options for their patients.
Why it matters
Potential benefit: If successful, patients could receive clearer treatment guidance that reduces vision loss and minimizes treatment-related side effects.
How similar studies have gone: Previous work suggests variability in response to antivirals and a lack of definitive comparative data, making this approach novel and potentially practice-changing.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Gonzales, John Alexander — University of California, San Francisco
- Study coordinator: Gonzales, John Alexander
Related research
Other NIH-funded projects on the same topics.
-
Adalimumab Dose Adjustment for Pediatric Uveitis in JIA
A pediatric study will test whether lowering how often kids with juvenile idiopathic arthritis–related uveitis take adalimumab can keep inflammation controlled while reducing side effects and cost.
-
Changing adalimumab dosing for children with juvenile arthritis–related eye inflammation
This project tries to see if giving lower or less frequent doses of adalimumab can keep eye inflammation under control in children with juvenile idiopathic arthritis.
-
Systemic and topical antiviral treatment for CMV anterior uveitis (STACCATO)
A new NIH-supported effort will test how well oral and eye-applied antiviral medicines control CMV-related anterior uveitis in affected patients.
-
Systemic and topical antiviral treatment for CMV anterior uveitis in patients
A patient-friendly look at using antiviral medicines to treat CMV-related eye inflammation and protect vision.
-
Systemic and topical antiviral treatment for CMV anterior uveitis
This project tests how oral and eye-drop antiviral medicines can help prevent vision loss from CMV-related eye inflammation in people with anterior uveitis.
-
AI tool to standardize how uveitis is measured
This project builds an AI platform to consistently measure signs of posterior uveitis in lab models so researchers can compare and improve treatments for people with uveitis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.